AI Article Synopsis
- The study investigates the effectiveness and side effects of split-course hypo-fractionated radiotherapy combined with chemotherapy (HFRT-CHT) using intensity-modulated radiotherapy (IMRT) for patients with postoperative locoregional recurrence (LRR) of non-small cell lung cancer (NSCLC).
- A total of 58 patients were analyzed, revealing a 2-year progression-free survival (PFS) rate of 59.7% and an overall survival (OS) rate of 72.5%, with only moderate side effects reported.
- Factors like performance status, site of recurrence, and tumor size significantly influenced PFS and OS outcomes, indicating that better patient conditions and less extensive disease led to improved survival rates.
Article Abstract
Objectives: To explore the efficacy and toxicities of split-course hypo-fractionated radiotherapy with concurrent chemotherapy (HFRT-CHT) with intensity modulated radiotherapy (IMRT) technique in non-small cell lung cancer (NSCLC) patients with postoperative locoregional recurrence (LRR).
Materials And Methods: NSCLC patients were eligible if confirmed as LRR disease without distant metastasis after complete resection. HFRT-CHT using IMRT technique was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break. Patients with no disease progression and no persistent Grade ≥2 toxicities had the second course of 15 Gy in 5 fractions or 28 Gy in 7 fractions as a boost. The primary endpoint was progression-free survival (PFS).
Results: Fifty-eight patients were enrolled and analyzed. With a median follow-up of 23.9 months for all, the 2-year and 3-year PFS rate was 59.7 % and 46.4 %, the 2-year and 3-year OS rate was 72.5 % and 52.2 %, respectively, and a favorable objective response rate of 95.9 % was obtained after the whole courses protocol. Grade 3 acute pneumonitis and esophagitis occurred in 2 (3.4 %) and 7 (12.1 %) patients, and fatal pneumonitis was reported in one case (1.7 %). Exploratory subgroup analysis showed that performance status (PS) (PS 0 vs. 1: 2-year PFS, 88.1 % vs. 46.9 %,P = 0.001; 2-year OS, 100 % vs. 59.4 %, P < 0.001), recurrence site (single vs. multiple: 2-year PFS, 93.8 % vs. 47.4 %, P = 0.008; 2-year OS, 100 % vs. 63.0 %, P = 0.001), and gross tumor volume (GTV) (<50cm vs. ≥ 50cm: 2-year PFS, 70.6 % vs. 46.2 %, P = 0.024; 2-year OS, 85.6 % vs. 57.4 %, P = 0.034) were significantly associated with PFS and OS.
Conclusion: Split-course HFRT-CHT with IMRT technique achieved promising disease control and satisfactory survival with moderate toxicities in postoperative LRR of NSCLC. Good PS, a single recurrence site and GTV<50cm tended to have prolonged PFS and OS. Early detection of LRR may improve the efficacy of HFRT-CHT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lungcan.2021.04.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the outcomes of MR-based versus CT-based tumor delineation in locally advanced non-small cell lung cancer treated with hypo-fractionated radiotherapy and concurrent chemotherapy.
Transl Lung Cancer Res
November 2024
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Article Synopsis
- The study compares magnetic resonance imaging (MRI) and computed tomography (CT) for tumor delineation in patients with locally advanced non-small cell lung cancer undergoing hypo-fractionated concurrent chemoradiotherapy.
- MRI provided better soft-tissue resolution, which resulted in a smaller planning target volume and fewer cases of severe toxicity compared to CT.
- There were no significant differences in locoregional progression-free survival, progression-free survival, or overall survival between the MRI-based and CT-based groups.
Comparison of online adaptive and non-adaptive magnetic resonance image-guided radiation therapy in prostate cancer using dose accumulation.
Phys Imaging Radiat Oncol
October 2024
Section for Biomedical Physics, Department of Radiation Oncology, University of Tübingen, Germany.
Article Synopsis
- Conventional image-guided radiotherapy (conv-IGRT) for prostate cancer fails to account for anatomical changes between treatment sessions, while online-adaptive magnetic resonance guided radiotherapy (OA-MRgRT) has potential for better sparing of critical organs and improved targeting.
- The study analyzed dose accumulation in ten prostate cancer patients treated with OA-MRgRT versus conv-IGRT, using advanced imaging techniques for dose mapping.
- Results showed that while both methods yielded similar target dose parameters, OA-MRgRT delivered lower doses to organs-at-risk like the rectum and bladder compared to conv-IGRT, though these differences didn't lead to clinically significant outcomes.
Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.
Radiother Oncol
January 2025
Department of Head & Neck Oncology, All India Institute of Medical Sciences, New Delhi, India.
Purpose: Radiotherapy is frequently employed for palliative treatment in locally advanced head and neck squamous cell carcinoma (HNSCC) but radiation dose fractionation regimens are not well-defined. We designed this phase 3 randomized controlled trial to compare two weekly hypo fractionated regimes and study the effect on progression-free survival (PFS) in this subset of patients.
Materials And Methods: Non-metastatic locally advanced HNSCC patients (n = 305) who were not suitable for curative treatment were randomized to Arm A (20 Gy/5#/5 days) and Arm B (30 Gy/5#/5 days).
Geriatric determinants of curative radiotherapy scheme choice for older adults with breast cancer treatment compliance and tolerance: Results from the GERABEL study.
J Geriatr Oncol
January 2025
Department of Radiation Oncology, CHU Saint-Etienne, Saint-Etienne, France; Department of Radiation Oncology, Institut Bergonié, Bordeaux, France.
Introduction: Chronological and functional aging complicates care in older patients, and therapeutic decisions need to consider individual needs to minimise morbidity and mortality. Therapeutic decisions should be guided by a multidisciplinary geriatric assessment, allowing a complete assessment of physical and functional performance. In this context, the GERABEL study aimed to orientate the irradiation strategy based on a detailed oncogeriatric assessment in women more than 70 years old with breast cancer.
View Article and Find Full Text PDFBreast cancer radiobiology: The renaissance of whole breast radiation fractionation (Review).
Mol Clin Oncol
December 2024
Department of Radiation Oncology, King Hussein Cancer Center, Amman 11941, Jordan.
Breast cancer radiotherapy has evolved significantly, driven by decades of research into fractionation schedules aimed at optimizing treatment efficacy and minimizing toxicity. Initial trials such as NSABP B-06 and EBCTCG meta-analyses established the benefits of adjuvant whole-breast irradiation in reducing local recurrence and improving survival rates. The linear-quadratic (LQ) model provided a framework to understand tissue response to radiation, highlighting the importance of the α/β ratio in determining fractionation sensitivity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!